Relay Therapeutics, Inc.
RLAYNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $15.4M | $10.0M | $25.5M | $1.4M | $3.0M | $82.7M |
| Operating income | −$302.7M | −$372.5M | −$373.0M | −$299.3M | −$364.7M | −$55.8M |
| Net income | −$276.5M | −$337.7M | −$342.0M | −$290.5M | −$363.9M | −$52.4M |
| Total assets | $621.3M | $871.3M | $844.0M | $1.10B | $1.01B | $799.8M |
| Total liabilities | $54.3M | $93.5M | $92.0M | $149.6M | $110.6M | $36.5M |
| Equity | $567.1M | $777.8M | $752.0M | $950.2M | $897.8M | $763.3M |
| EPS (diluted) | $-1.61 | $-2.36 | $-2.79 | $-2.59 | $-3.82 | $-5.40 |
| Shares out. | 169.5M | 131.2M | 121.4M | 108.3M | 90.4M | 89.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −1971.6%
- Net margin
- −1800.6%
- Return on equity
- −48.8%
- Return on assets
- −44.5%
- Return on capital (ROCE)
- −50.8%
- Liabilities / assets
- 8.7%
- Debt / equity
- 0.10×
- Book value / share
- $3.35
- Revenue growth (YoY)
- 53.4%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 2.96safe
- Accruals / assets
- −6.6%clean
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 3 warning● 4 good- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Recruitingreadout ~2027-04-30First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- Phase 1Recruitingreadout ~2027-12-30A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
- Phase 3Recruitingreadout ~2028-04-30Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Phase 2Recruitingreadout ~2031-07A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Point72 Asset Management, L.P.Passive (13G)May 15, 2026
- Perceptive Advisors LlcPassive (13G)Apr 13, 2026
- Vanguard Group IncPassive (13G)Mar 27, 2026
- Casdin Capital, LlcPassive (13G)Feb 17, 2026
- Commodore Capital LpPassive (13G)Nov 14, 2025
- Blackrock, Inc.Passive (13G)Apr 17, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 28.8M | 10.3 | +5.2% |
| Apr 30, 2026 | 27.4M | 8.7 | +1.5% |
| Apr 15, 2026 | 27.0M | 6.2 | +23.1% |
| Mar 31, 2026 | 21.9M | 10.3 | +10.6% |
| Mar 13, 2026 | 19.8M | 6.4 | +2.1% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreementMay 21, 2026
- Regulation FD disclosure · Other material eventMay 19, 2026
- Results of operationsMay 5, 2026
- Regulation FD disclosure · Other material eventApr 27, 2026
- Regulation FD disclosure · Other material eventMar 16, 2026
- Amended charter or bylawsMar 11, 2026
- Results of operationsFeb 26, 2026
- Regulation FD disclosure · Other material eventFeb 3, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.